Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral neutralization assays
Gilda Lemos(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Beatriz Álvarez-Acevedo(PRA Health Sciences), Ariel Palenzuela-Díaz(Center of Molecular Immunology (Cuba)), Lismary Ávila-Díaz(Centro de Ingeniería Genética y Biotecnología), Amalia Vázquez-Arteaga(Centro de Ingeniería Genética y Biotecnología), Hany González-Formental(Centro de Ingeniería Genética y Biotecnología), Sheila Chávez-Valdés(Centro de Ingeniería Genética y Biotecnología), Ricardo Martínez-Rosales(Centro de Ingeniería Genética y Biotecnología), Yahima Chacón-Quintero(Centro de Ingeniería Genética y Biotecnología), Giselle Freyre-Corrales(Centro de Ingeniería Genética y Biotecnología), Edelgis Coizeau-Rodríguez(Centro de Ingeniería Genética y Biotecnología), Enrique Noa-Romero
Cited by 8
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134